

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **October 15, 2024**

**BULLFROG AI HOLDINGS, INC.**

(Exact name of registrant as specified in charter)

**Nevada**  
(State or other jurisdiction  
of incorporation)

**001-41600**  
(Commission  
File Number)

**84-4786155**  
(IRS Employer  
Identification No.)

**325 Ellington Blvd, Unit 317  
Gaithersburg, MD 20878**  
(Address of principal executive offices) (Zip Code)

**(240) 658-6710**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$ 0.00001 per share	BFRG	The Nasdaq Stock Market LLC (The Nasdaq Capital Market)
Tradeable Warrants	BFRGW	The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure**

On October 15, 2024, Bullfrog AI Holdings, Inc. issued a press release. A copy of the press release is attached hereto and incorporated herein by reference in its entirety as [Exhibit 99.1](#).

**Item 9.01 Financial statements and Exhibits**

(d) Exhibits.

**Exhibit  
Number**      **Description**

Exhibit 99.1      [Press Release dated October 15, 2024](#)

104      Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 15, 2024

**BULLFROG AI HOLDINGS, INC.**

By: /s/ Vininder Singh

Vininder Singh  
Chief Executive Officer

---

**BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni**

GAITHERSBURG, Md. – October 15, 2024 – BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of John Baldoni, Ph.D., to its Scientific Advisory Board. Dr. Baldoni brings over four decades of experience in the pharmaceutical industry, including leadership roles in scientific research and technology-driven drug discovery.

Dr. Baldoni’s career includes 29 years in R&D at GSK, where he served as Senior Vice President of Platform and Technology Sciences, leading critical innovations in drug discovery and development. He has contributed to the development of scores of commercial products. John is the co-founder of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium, a groundbreaking public-private partnership aimed at revolutionizing drug development and is the former Chair of the Executive Committee of the Alliance for Artificial Intelligence in Healthcare. John currently holds leadership and board roles at several innovative companies operating at the confluence of data, machine learning and healthcare needs.

“We are pleased to welcome Dr. Baldoni to our Scientific Advisory Board,” said Vin Singh, CEO of BullFrog AI. “His extensive experience in pharmaceutical R&D, coupled with his leadership in advancing technology-driven drug discovery, will be an asset to our team, providing unique insights that will help guide the commercialization of our bLEAP™ platform and drive innovation in drug development.”

Dr. Baldoni added, “I am excited to collaborate with BullFrog AI, a company at the forefront of leveraging AI to improve drug discovery and development. The potential of the bLEAP™ platform to transform the way we approach complex biological data is immense, and I look forward to contributing to the company’s growth and success.”

**About BullFrog AI**

BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.

For more information visit BullFrog AI at: <https://bullfrogai.com>

**Safe Harbor Statement**

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

**Contact:**

Dave Gentry  
RedChip Companies, Inc.  
1-407-644-4256  
[BFRG@redchip.com](mailto:BFRG@redchip.com)

---